Autologous Hematopoietic Stem-Cell Transplantation for Malignant Astrocytomas and Gliomas

Policy # 00058
Original Effective Date: 01/28/2002
Current Effective Date: 09/21/2016

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers autologous hematopoietic stem cell transplantation (HSCT) as a treatment of malignant astrocytomas and gliomas to be investigational.* (The latter diagnosis includes both glioblastoma multiforme and oligodendroglioma.)

Background/Overview
Malignant glial tumors are usually resistant to conventional treatment approaches. Autologous HSCT has been investigated as a treatment for malignant astrocytomas and gliomas.

Hematopoietic Stem-Cell Transplantation
Hematopoietic stem-cell transplantation (HSCT) refers to a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of cytotoxic drugs with or without whole-body radiation therapy. Bone marrow stem cells may be obtained from the transplant recipient (autologous HSCT) and can be harvested from bone marrow, peripheral blood, or umbilical cord blood and placenta shortly after delivery of neonates. Although cord blood is an allogeneic source, the stem cells in it are antigenically “naïve” and thus are associated with a lower incidence of rejection or graft-versus-host disease.

Preparative Conditioning for Hematopoietic Stem-Cell Transplantation
Autologous HSCT necessitates myeloablative chemotherapy to eradicate cancerous cells from the blood and bone marrow, thus permitting subsequent engraftment and repopulation of bone marrow space with presumably normal hematopoietic progenitor cells. As a consequence, autologous HSCT is typically performed as consolidation therapy when the patient’s disease is in complete remission. Patients who undergo autologous HSCT are susceptible to chemotherapy-related toxicities and opportunistic infections prior to engraftment but not graft-versus-host disease.

Astrocytomas and Gliomas
Diffuse fibrillary astrocytomas are the most common type of brain tumor in adults. These tumors are classified histologically into 3 grades of malignancy: grade II astrocytoma, grade III anaplastic astrocytoma, and grade IV glioblastoma multiforme. Oligodendrogliomas are diffuse neoplasms that are clinically and biologically most closely related to diffuse fibrillary astrocytomas. However, these tumors generally have better prognoses than diffuse astrocytomas, with mean survival times of 10 years versus 2–3 years, respectively. In addition, oligodendrogliomas appear to be more chemosensitive than other types of...
Autologous Hematopoietic Stem-Cell Transplantation for Malignant Astrocytomas and Gliomas

Policy # 00058
Original Effective Date: 01/28/2002
Current Effective Date: 09/21/2016

Astrocytomas. Glioblastoma multiforme is the most malignant stage of astrocytoma, with survival times of less than 2 years for most patients.

Treatment of primary brain tumors focuses on surgery, either with curative intent or optimal tumor debulking. Surgery may be followed by radiation therapy and/or chemotherapy. Survival after chemoradiotherapy is largely dependent on the extent of residual tumor after surgical debulking. Therefore, tumors arising in the midline, basal ganglia, or corpus callosum or those arising in the eloquent speech or motor areas of the cortex, which typically cannot be extensively resected, have a particularly poor outcome. Treatment of children younger than 3 years is complicated by the long-term effects of radiation therapy on physical and intellectual function. Therefore, in young children, radiation of the central nervous system (CNS) is avoided whenever possible.

Note: Astrocytomas and gliomas arise from the glial cells. Tumors arising from the neuroepithelium constitute a separate category of malignancies that include CNS neuroblastoma, medulloblastoma, ependymoblastomas, and pinealoblastomas. Collectively these tumors may be referred to as primitive neuroectodermal tumors (PNETs). Ependymomas also arise from the neuroepithelium but, because of their more mature histologic appearance, are not considered a member of the PNET family.

Rationale/Source
An updated literature search through June 7, 2013 identified no controlled studies that would change the conclusions of this policy. The published literature consists primarily of single-institution case series.

Bouffet and colleagues reported on a series of 22 children and young adults with high-grade gliomas treated with autologous HSCT. The response rate was 29% with 1 complete and 3 partial responses. However, the authors concluded that survival with this procedure was no better than that reported with conventional treatments. Heideman and colleagues reported on a case series of 13 pediatric patients with bulky disease or recurrent disease treated with HSCT plus radiotherapy. While the overall response rate was 31%, the authors similarly concluded that overall survival was no better than conventional treatment regimens. Finlay and colleagues reported on a 1996 case series of 45 children and young adults with a variety of recurrent CNS tumors, including gliomas, medulloblastomas, ependymomas, and primitive neuroectodermal tumors. Of the 18 patients with high-grade gliomas, the response rate was 29%. The median survival of this group was 12.7 months. Of the 5 long-term survivors, all had high-grade glioma with minimal residual disease at the time of transplantation. Based in part on these results, the authors recommended aggressive surgical debulking before this procedure is even considered. Studies focusing on the use of autologous HSCT in adults with glioblastoma multiforme reported results similar to those in children, being most successful in those with minimal disease at the time of treatment, with an occasional long-term survivor.

A review by Brandes and colleagues concluded that the high drug doses used in this treatment caused excessive toxicity that was not balanced by a significant improvement in survival. Additional reports on small, uncontrolled series of patients with pontine gliomas, recurrent oligodendrogliomas, or those undergoing radiation therapy for high-grade gliomas also did not suggest that this treatment improves survival. In a Phase II study, Abrey and colleagues evaluated hematopoietic stem-cell transplantation in 39
Autologous Hematopoietic Stem-Cell Transplantation for Malignant Astrocytomas and Gliomas

Policy # 00058
Original Effective Date: 01/28/2002
Current Effective Date: 09/21/2016

patients with newly diagnosed oligodendroglioma. The authors reported the median follow-up of surviving patients was 80.5 months, with 78 months progression-free survival. The overall survival median had not been reached, and 18 patients (46%) had relapsed.

A nonrandomized study compared survival outcomes of 27 children (age, 0.4–22 years) with recurrent malignant astrocytomas who underwent myeloablative chemotherapy and autologous HSCT with outcomes in a matched historical cohort (n=56) that received standard chemotherapy regimens following tumor recurrence. Among the 27 children who received myeloablative chemotherapy and autologous HSCT, 5 (18%) succumbed to treatment-related toxicities within approximately 2 months of transplantation, 17 (63%) had disease progression, while 5 survived and were alive a median of 11 years (range: 8–13 years) after transplantation. Overall survival rates at 4 years were 40 ± 14% for transplant patients versus 7 ± 4% with conventional chemotherapy (p=0.018, hazard ratio [HR]: 1.9; 95% confidence interval [CI]: 1.1–3.2). The results of this study suggest myeloablative chemotherapy with autologous HSCT can produce long-term survival among children with recurrent malignant astrocytoma. However, lack of a contemporaneous treatment comparison group precludes conclusions as to the relative efficacy of this approach.

A comprehensive review article identified in the search did not report any evidence for the role of HSCT in this disease.

Summary
The data on the use of autologous hematopoietic stem-cell transplantation for malignant astrocytomas and gliomas, consisting of case series, has, in general, shown no survival benefit compared to conventional therapy with increased treatment-related toxicity. Therefore, this is considered investigational for this indication.

National Cancer Institute Physician Data Query (PDQ) Clinical Trials Database
A search in June 2013 found one active U.S. Phase II trial of HSCT for newly diagnosed central nervous system tumors, including glioblastoma multiforme and gliosarcoma (NCT00669669). This study is currently recruiting participants (N=24) with the estimated completion date of February 2017.

National Comprehensive Cancer Network (NCCN) Guidelines

References
Autologous Hematopoietic Stem-Cell Transplantation for Malignant Astrocytomas and Gliomas

Policy # 00058
Original Effective Date: 01/28/2002
Current Effective Date: 09/21/2016


Policy History
Original Effective Date: 01/28/2002
Current Effective Date: 09/21/2016
12/06/2001 Medical Policy Committee review
01/28/2002 Managed Care Advisory Council approval
03/31/2004 Medical Director review
04/20/2004 Medical Policy Committee review. High-dose chemotherapy and hematopoietic stem cell support for treatment of malignant astrocytomas and gliomas policy developed separately from current HDC with Hematopoietic Stem cell Support policy. Coverage eligibility unchanged.
04/26/2004 Managed Care Advisory Council approval
04/05/2006 Medical Director review
04/19/2006 Medical Policy Committee review. Format revision, including addition of FDA and or other governmental regulatory approval and rationale/ source.
04/04/2007 Medical Director review
04/18/2007 Medical Policy Committee approval. No change to coverage eligibility.
04/02/2009 Medical Director review
04/15/2009 Medical Policy Committee approval. Changed title to "Autologous Hematopoietic Stem Cell Transplantation for Malignant Astrocytomas and Gliomas". Clarified investigational coverage statement by adding the phrase, "including glioblastoma multiforme and oligodendroglioma". No change to coverage eligibility.
04/08/2010 Medical Policy Committee approval
04/21/2010 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
04/07/2011 Medical Policy Committee review
04/12/2012 Medical Policy Committee review
04/25/2012 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/19/2013 coding updated
04/04/2013 Medical Policy Committee review

©2016 Blue Cross and Blue Shield of Louisiana
An independent licensee of the Blue Cross and Blue Shield Association
No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 4 of 6
Autologous Hematopoietic Stem-Cell Transplantation for Malignant Astrocytomas and Gliomas

Policy # 00058
Original Effective Date: 01/28/2002
Current Effective Date: 09/21/2016

04/24/2013 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
04/03/2014 Medical Policy Committee review
08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
09/03/2015 Medical Policy Committee review
09/08/2016 Medical Policy Committee review
09/21/2016 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
Next Scheduled Review Date: 9/2017

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2015 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms.

Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>38204, 38206, 38207, 38208, 38209, 38210, 38211, 38212, 38213, 38214, 38215, 38232, 38241, 38242, 38243</td>
</tr>
<tr>
<td>HCPCS</td>
<td>S2150</td>
</tr>
<tr>
<td>ICD-10</td>
<td>C71.0-C71.9</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

©2016 Blue Cross and Blue Shield of Louisiana
An independent licensee of the Blue Cross and Blue Shield Association
No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 5 of 6
Autologous Hematopoietic Stem-Cell Transplantation for Malignant Astrocytomas and Gliomas

Policy # 00058
Original Effective Date: 01/28/2002
Current Effective Date: 09/21/2016

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

† Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.